Meeting
2021 ASCO Annual Meeting
A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).
Authors
Marcos J.G. De Lima
University Hospitals Cleveland Medical Center, Cleveland, OH
Marcos J.G. De Lima , Partow Kebriaei , Francesco Lanza , Christina Cho , Sergio Giralt , Gizelle Popradi , Michael T Hemmer , Xin Zhang , Richa Shah , Verna L. Welch , Erik Vandendries , Matthias Stelljes , David I. Marks , Wael Saber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7017)
DOI
10.1200/JCO.2021.39.15_suppl.7017
Abstract #
7017
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT).
First Author: Max Topp
Poster
2018 ASCO Annual Meeting
Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.
First Author: Ryan Daniel Cassaday
Poster
2024 ASCO Annual Meeting
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Olalekan O. Oluwole
Poster
2023 ASCO Annual Meeting
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Bijal D. Shah